A compound as shown in formula I, or an optical isomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a
prodrug thereof, a
tautomer thereof, a mesomer thereof, a racemate thereof, an
enantiomer thereof, a
diastereomer thereof, a mixture form thereof, a
metabolite thereof, a metabolic precursor thereof, or an
isotope substitute form thereof. TB is a target recognition / binding portion, L is a linking portion, and U is a
ubiquitin protease recognition / binding portion, the three portions being connected by means of chemical bonds. The compound can significantly down-regulate mutated
androgen receptor (AR) proteins, and has good inhibitory activity on
prostate cancer cell lines. The compound of formula I can be used for preparation of a
protein degradation targeted chimera for targeted regulation of
androgen receptors, and a
drug for treating diseases correlated with regulation by
androgen receptors, and has particularly good application prospects in drugs for treating
prostate cancers and breast cancers.